The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Study ID: NCT03163667
Brief Summary: The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following: * At least 2 lines of therapy, including at least 1 vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) * Radiographic progression of metastatic RCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to cycle 1 day 1
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The University of Arizona Cancer Center, Tucson, Arizona, United States
Highlands Oncology Group, Rogers, Arkansas, United States
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
Stanford Cancer Center, Stanford, California, United States
Florida Cancer Specialists- South, Fort Myers, Florida, United States
Florida Cancer Specialists- North, Saint Petersburg, Florida, United States
University Cancer & Blood Center, LLC, Athens, Georgia, United States
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
St. Luke's Mountain States Tumor Institute, Boise, Idaho, United States
Northwestern University, Chicago, Illinois, United States
Parkview Research Center, Fort Wayne, Indiana, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States
Ochsner Clinical Foundation, New Orleans, Louisiana, United States
Anne Arundel Medical Center Oncology and Hematology, Annapolis, Maryland, United States
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
Mercy Clinic Oncology & Hematology, Joplin, Missouri, United States
SCRI HCA Midwest, Kansas City, Missouri, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
St. Vincent Frontier Cancer Center, Billings, Montana, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Montefiore Medical Center, Bronx, New York, United States
North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists, East Setauket, New York, United States
NYU Winthrop Hospital - Cancer Clinical Trials Oncology/Hematology, Mineola, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
SUNY Upstate Medical University, Syracuse, New York, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Ann B. Barshinger Cancer Institute / Lancaster General Hospital, Lancaster, Pennsylvania, United States
Monongahela Valley Hospital, Monongahela, Pennsylvania, United States
Charleston Hematology Oncology Associates,PA, Charleston, South Carolina, United States
UT/Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States
Sarah Cannon Research Institute - Tennessee Oncology, Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Utah Cancer Specialists, Salt Lake City, Utah, United States
Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Name: Sam Whiting
Affiliation: Calithera Biosciences
Role: STUDY_DIRECTOR